Wall Street Journal -- LONDON—The low level of successful drug innovation from the pharmaceuticals industry represents a major public health concern and an enormous waste of money and needs to be addressed by drug makers and their regulators, the outgoing executive director of the European Medicines Agency said Wednesday.
